Investor Relations
About InMed Pharmaceuticals
InMed Pharmaceuticals is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications.
Together with its subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs.
Corporate Highlights
- Robust R&D pipeline with 3 candidates in dermatology, ocular and Alzheimer’s
- A successful Phase 2 dermatology program, currently seeking partnerships
- Library of proprietary analogs targeting diverse pharmaceutical applications
- A revenue generating subsidiary selling rare cannabinoids to the H&W industry
- Diverse product portfolio of bioidentical non-intoxicating rare cannabinoids
- Consistent revenue growth including 278% YoY F2023 v F2022
- Broad range of IP across molecules, manufacturing, formulations and methods of use